公开(公告)号：PT2017269E

公开(公告)日：2011-12-20

申请号：PT08007622

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  PATEL KETAN ,  SPIWEK HARRY O ,  CHEMBURKAR SANJAY R ,  SALEKI-GERHARDT AZITA

IPC: C07D277/24 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

公开(公告)号：BG65963B1

公开(公告)日：2010-07-30

申请号：BG10968206

申请日：2006-09-20

Applicant: ABBOTT LAB

Inventor： BAUER JOHN ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL ,  CHEMBURKAR SANJAY ,  PATEL KETAN ,  SPIWEK HARRY ,  BAUER PHILIP ,  ALLEN KIMBERLY

IPC: C07D277/24 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/00 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: The invention relates to (2S,3S,5S)-5-{N-[N-(/N-methyl-N-[/2-isopropyl-4-thiazolyl/methyl]amino}carbonyl-L-valinyl)amino]-2-{N-[/5- thiazolyl/methoxycarbonyl]amino}-1,6-diphenyl-3-hydroxyhexane} (ritonavir), in particular to essentially pure amorphous ritonavir, to methods of obtaining it, to pharmaceutical compositions containing it, as well as to a method of obtaining essentially pure crystalline polymorphous forms I and II of ritonavir.

公开(公告)号：HK1121155A1

公开(公告)日：2009-04-17

申请号：HK09100857

申请日：2009-01-29

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O

IPC: A61K20060101 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D20060101 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：SK286388B6

公开(公告)日：2008-09-05

申请号：SK922001

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: A61K31/00 ,  A61K31/426 ,  A61K31/427 ,  A61P31/00 ,  A61P31/18 ,  A61P37/00 ,  A61P37/04 ,  C07D277/00 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/00 ,  C07D417/12

Abstract: Described is a crystalline polymorph of ritonavir and methods for its use and preparation.

公开(公告)号：PL194710B1

公开(公告)日：2007-06-29

申请号：PL34803399

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: C07D277/24 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：BG65150B1

公开(公告)日：2007-04-30

申请号：BG10519701

申请日：2001-01-30

Applicant: ABBOTT LAB

Inventor： BAUER JOHN ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL ,  CHEMBURKAR SANJAY ,  PATEL KETAN ,  SPIWEK HARRY ,  BAUER PHILIP ,  ALLEN KIMBERLY

IPC: A61K31/426 ,  A61K31/427 ,  A61P31/00 ,  A61P31/18 ,  A61P37/00 ,  A61P37/04 ,  C07D277/00 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: The invention relates to a new crystalline polymorphic form of (2S,3S,5S)-5-{N-[N-(/N-methyl-N-[/2-isopropyl-4-thiazolyl/methyl]amino/carbonyl-L-valinyl)amino]-2-{N-/5-thiazolyl/methoxicarbonyl]amino}-1,6-diphenyl-3-xydroxyhexan} (ritonavir), to a method of obtaining it, and to pharmaceutical compositions containing it.

公开(公告)号：DE69628575T2

公开(公告)日：2004-04-29

申请号：DE69628575

申请日：1996-10-18

Applicant: ABBOTT LAB

Inventor： SALEKI-GERHARDT AZITA ,  KESKE R

IPC: A61K9/16 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K47/32

Abstract: The present invention provides a process for the aqueous granulation of a macrolide antibiotic which comprises mixing a macrolide antibiotic and a carbomer; wetting the mixture with water; and blending the mixture to allow formation of a macrolide antibiotic-carbomer granule.

公开(公告)号：AU768207B2

公开(公告)日：2003-12-04

申请号：AU5003799

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12 ,  C07D417/00

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：CA2235607C

公开(公告)日：2003-05-13

申请号：CA2235607

申请日：1996-10-18

Applicant: ABBOTT LAB

Inventor： SALEKI-GERHARDT AZITA ,  KESKE ERNEST R

IPC: A61K9/16 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K47/32 ,  A61K31/71 ,  B01J2/00

Abstract: The prevent invention provides a process for the aqueous granulation of a macrolide antibiotic which comprises mixing a macrolide antibiotic and a carbomer; wetting the mixture with water; and blending the mixture to allow formation of a macrolide antibiotic-carbomer granule.

公开(公告)号：PE20030098A1

公开(公告)日：2003-02-12

申请号：PE2002000436

申请日：2002-05-24

Applicant: ABBOTT LAB

Inventor： BARBATO ALESSANDRO ,  PETRICONI SERGIO ,  URCH MARTIN ,  SCUPPA ROBERTA ,  SALEKI-GERHARDT AZITA

IPC: A61K9/48 ,  A61K31/426 ,  A61K31/427 ,  A61K31/513 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34 ,  A61P31/18

Abstract: LA CAPSULA COMPRENDE: I)UN RELLENO, QUE A SU VEZ CONTIENE: i)UN AGENTE O COMBINACION DE AGENTES FARMACEUTICOS, TAL COMO UN INHIBIDOR DE VIH SOLUBILIZADO QUE ES (2S,3S,5S)-5-(N-(N-((N-metil-N-N-((2-isopropil-4-tiazolil)-metil)amino)carbonil)-L-valinil)amino-2-(N-((5-tiazolil)metoxi-carbonil)-amino-1,6-difenil-3-hidroxihexano(ritonavir); ii)UN ALCOHOL; Y, iii)UN ACIDO GRASO; Y II)UN REVESTIMIENTO, QUE A SU VEZ COMPRENDE: 1)GELATINA; Y, 2)POR LO MENOS UN AGENTE PLASTIFICANTE. DONDE (II) TIENE UN ESTADO INICIAL Y UN ESTADO DE EQUILIBRIO; DE MANERA QUE EN EL ESTADO INICIAL SE SUBPLASTIFICA Y (I) CONTIENE UNA CANTIDAD EN EXCESO DE ALCOHOL RESPECTO DE LA CANTIDAD NECESARIA PARA SOLUBILIZAR EL AGENTE FARMACEUTICO Y DICHO ALCOHOL NO ESTA PRESENTE EN EL ESTADO INICIAL DE LA COMPOSICION DE REVESTIMIENTO, Y EN EL ESTADO DE EQUILIBRIO SE PLASTIFICA EL REVESTIMIENTO MEDIANTE EL ALCOHOL PROVENIENTE DEL RELLENO PARA PROPORCIONAR UNA DUREZA DE CAPSULA APROPIADA Y EL RELLENO RETIENE SUFICIENTE ALCOHOL COMO PARA MANTENER AL AGENTE FARMACEUTICO EN SOLUCION